New-Generation Tetanus Prophylaxis Agent Sintetol Now Covered by Zhuhai’s "Da Ai Wu Jiang" Program
On April 16, Zhuhai Trinomab BioPharmaceutical Co., Ltd. (hereinafter "Trinomab") announced that its self-developed a first-in class recombinant monoclonal antibody drug, a next-generation tetanus prophylaxis agent, Sintetol (generic name: Siltartoxatug Injection), has been officially included in the compensation plan provided by the Zhuhai’s supplementary medical insurance program -"Da Ai Wu Jiang" (Love without boarder)." This innovative drug is indicated for emergency tetanus prophylaxis in adults.
Individuals aged 18 and above covered by this insurance plan can enjoy a 70% reimbursement rate with no deductible when using Sintetol at designated secondary or higher-tier medical institutions in Zhuhai. Treated with Sintetol priced at RMB 798 per vial, patients only pay RMB 239.4 out-of-pocket after reimbursement, substantially alleviating financial burdens. This news symbols a milestone of a transformative breakthrough in tetanus prevention in Zhuhai and nationwide. The initiative, jointly promoted by the Zhuhai Medical Security Bureau, Zhuhai Science & Technology Innovation Bureau and Zhuhai Health Bureau, aims to accelerate pharmaceutical innovation and commercialization through policy support.
Industry Empowerment: From the "Zhuhai Model" to Global Leadership
Amid global biopharmaceutical industry shifts, Zhuhai’s municipal government has prioritized fostering local innovation. The "Special Compensation Mechanism for Taxpaying Pharmaceutical Enterprises" exemplifies the integration of healthcare policy and industrial strategy.
At the launch ceremony, Cheng Zhitao, Director of the Zhuhai Medical Security Bureau, highlighted that this mechanism addresses the industry’s pain points of "long R&D cycles, high costs, and slow returns." For Sintetol, the 70% reimbursement directly reduces patient costs while accelerating cost recovery for enterprises, creating a "market-driven R&D" virtuous cycle. This policy also establishes a rapid "clinical validation-to-reimbursement" pathway, positioning medical institutions as early adopters of innovative therapies and elevating regional healthcare standards.
Public Benefit: 70% Reimbursement Enhances Access to Innovation
Lai Xiaobo, Deputy General Manager of China Life’s Zhuhai Branch, detailed that the "Da Ai Wu Jiang" program currently covers 1.138 million residents, with cumulative payouts reaching RMB 774 million, benefiting 173,400 individuals. Sintetol is now available at four hospitals in Zhuhai: Zhuhai People’s Hospital, Zhuhai Fifth People’s Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine (Zhuhai Branch), and Guangdong Provincial People’s Hospital (Jinwan Central Hospital).
"This initiative bridges clinical needs with policy innovation," stated Dr. Chen Muqing, an emergency physician at Zhuhai People’s Hospital. "It not only enhances accessibility to advanced therapies but also ensures affordability through low premiums and broad eligibility, meeting urgent patient demands."
Corporate Responsibility: Trinomab donated 2,000 "Da Ai Wu Jiang" insurance policies to the Guangmingxing Charity Foundation for people with special needs and underprivileged during the ceremony, demonstrating corporate social responsibility . This act underscores the company’s commitment to equitable healthcare access.
Sintetol: A Global First with Four Breakthrough Advantages
Approved by China’s NMPA on February 11, 2025, Sintetol is the world’s first recombinant anti-tetanus toxin monoclonal antibody drug. Administered via intramuscular injection, it provides rapid protection without skin testing, post-dose observation (for outpatients), or dose adjustments based on weight or wound severity. Its inclusion in "Da Ai Wu Jiang" exemplifies Zhuhai’s "policy-driven innovation" model.
Zhao Wengui, Vice President and Head of Commercial Operations at Trinomab, outlined Sintetol’s clinical advancements:
1. Proactive Protection Upgrade: Shifts from passive defense to precision prevention, neutralizing tetanus toxin at the infection onset.
2. Technological Revolution: Replaces century-old blood-derived products with recombinant DNA technology, ensuring safety and scalability.
3. Streamlined Administration: Eliminates complex protocols, enabling "one-shot" convenience.
4. Extended Protection: Closes the 13% coverage gap left by traditional agents, safeguarding patients with varying incubation periods (from<48 hours="" to="">30 days).
The inclusion of Sintetol in “Da Ai Wu Jiang” exemplifies Zhuhai’s strategy of “activating the innovation chain through policy support.” As a local enterprise rooted in Zhuhai, Trinomab has established a GMP-certified commercial production base in Jinwan District, ensuring stable mass production and resolving the historical shortage of traditional human tetanus immunoglobulin (HTIG), thus providing a reliable supply for the market.
With Sintetol’s launch, China’s tetanus prevention is transforming from a lagging system to a globally leading model. Starting from Zhuhai, the initiative accelerates the construction of a “prevention-oriented, precision-long-acting, and universally accessible” tetanus prevention framework, contributing to the Healthy China Strategy with Trinomab’s innovative strength.
(Sintetol Trademark Registration Number: 74174546)
